Using adaptive model predictive control to customize maintenance therapy chemotherapeutic dosing for childhood acute lymphoblastic leukemia

Journal of Theoretical Biology

Volumn 264, Issue 3, 2010, Pages 990-1002

  Noble, Sarah L ^a   Sherer, Eric ^b   Hannemann, Robert E ^a,c   Ramkrishna, Doraiswami ^c   Vik, Terry ^d   Rundell, Ann E ^a  

^a PURDUE UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PURDUE UNIVERSITY   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Biological systems; Drug scheduling; Hematopoietic stem cell differentiation; Nonlinear model predictive control; Personalized medicine

Indexed keywords

MERCAPTOPURINE; TIOGUANINE;

BLOOD; CANCER; CHEMOTHERAPY; CHILD HEALTH; DRUG; NUMERICAL MODEL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG RESPONSE; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; UNCERTAINTY;

6-MERCAPTOPURINE; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE INDICES; HUMANS; MODELS, BIOLOGICAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 77952669104     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.01.031     Document Type: Article

References (48)

1. Bailey, J.M., Haddad, W.M., 2005. Drug dosing control in clinical pharmacology. IEEE Control Systems Magazine, pp. 35-51.
2. Barrett J.S., Mondick J.T., Narayan M., Vijayakumar K., Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Medical Informatics and Decision Making 2008, 8.
3. Belaiche J., Desager J.P., Horsmans Y., Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scandinavian Journal of Gastroenterology 2001, 1:71-76.
4. Birtwistle M.R., Kholodenko B.N., Ogunnaike B.A. Experimental design for parameter identifiability in biological signal transduction modeling. Systems Analysis of Biological Networks 2009, Artech House, Boston. A. Jayaraman, J. Hahn (Eds.).
5. Bökkerink J.P.M., Stet E.H., De Abreu R.A., Damen F.J.M., Hulscher T.W., Bakker M.A.H., van Baal J.A. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochemical Pharmacology 1993, 45:1455-1463.
6. Bostrom B., Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. The American Journal of Pediatric Hematology/Oncology 1993, 15:80-86.
7. Buttarello M., Plebani M. Automated blood cell counts. American Journal of Clinical Pathology 2008, 130:104-116.
8. Chrzanowska M., Kolecki P., Duczmal-Cichocka B., Fiet J. Metabolites of mercaptopurine in red blood cells: a relationship between 6-tioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. European Journal of Pharmaceutical Sciences 1999, 8:329-334.
9. Cutnell J., Johnson K. Physics 1998, Wiley, New York. 4th ed.
10. Decaux G., Prospert F., Horsmans Y., Desager J.P. Relationship between red cell mean corpuscular volume and 6-thioguanine nucelotides in patients treated with azathioprine. Journal of Laboratory and Clinical Medicine 2000, 135:256-262.
11. Dua P., Doyle F.J., Pistikopoulos E.N. Model-based blood glucose control for type 1 diabetes via parametric programming. IEEE Transactions on Biomedical Engineering 2006, 53:1478-1491.
12. Dubinsky M.C., Reyes E., Ofman J., Chiou C.-F., Wade S., Sandborn W.J. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. American Journal of Gastroenterology 2005, 100:2239-2247.
13. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Parmacogenomics and individualized drug therapy. Annual Review of Medicine 2006, 57:119-137.
14. Evans W.E., Relling M.V., Rodman J.H., Crom W.R., Boyett J.M., Pui C.-H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. The New England Journal of Medicine 1998, 338:499-505.
15. Florian J.A., Eiseman J.L., Parker R.S. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model. Computers in Biology and Medicine 2008, 38:339-347.
16. Foley C., Mackey M.C. Dynamic hematological disease: a review. Journal of Mathematical Biology 2009, 58:285-322.
17. Henze G., Langermann H.-J., Ritter J., Schellong G., Riehm H. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM study group. Haematology and Blood Transfusion 1981, 26:87-93.
18. Hillman R.S., Finch C.A. Red Cell Manual 1996, F. A. Davis Company. 7th ed.
19. Hovorka R., Canonico V., Chassin L.J., Haueter U., Massi-Benedetti M., Federici M.O., Pieber T.R., Schaller H.C., Schaupp L., Vering T., Wilinska M.E. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiological Measurement 2004, 25:905-920.
20. Innocenti F., Danesi R., Favre C., Nardi M., Menconi M.C., Di Paolo A., Bocci G., Fogli S., Barbara C., Barachini S., Casazza G., Macchia P., Tacca M.D. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. Therapeutic Drug Monitoring 2000, 22:375-382.
21. Lennard L., Rees C.A., Lilleyman J.S., Maddocks J.L. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. British Journal of Clinical Pharmacology 1983, 16:359-363.
22. Lilleyman J.S., Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. The Lancet 1994, 343:1188-1190.
23. Lonnerholm G., Kreuger A., Lindstrom B., Myrdal U. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability. Pediatric Hematology/Oncology 1989, 6:105-112.
24. Mackey M.C. Unified hypothesis for the origin of aplastic anemia and periodic hematopoiesis. Blood 1978, 51:941-956.
25. Mauer A.M., Evert C.F., Lampkin B.C., McWilliams N.B. Cell kinetics in human acute lymphoblastic leukemia: computer simulation with discrete modeling techniques. Blood 1973, 41:141-154.
26. Morales A., Salguti S., Miao C.L., Lewis J.D. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2007, 13:380-385.
27. National Cancer Institute, 2009. Physician data query: childhood acute lymphoblastic leukemia treatment, U.S. National Institutes of Health.
28. Panetta J.C., Evans W.E., Cheok M.H. Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. British Journal of Cancer 2006, 94:93-100.
29. Panetta J.C., Iacono L.C., Adamson P.C., Stewart C.F. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clinical Cancer Research 2003, 9:5068-5077.
30. Panetta J.C., Yanishevski Y., Pui C.-H., Sandlund J.T., Rubnitz J., Rivera G.K., Ribeiro R., Evans W.E., Relling M.V. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy Pharmacology 2002, 50:419-428.
31. Parker R.S., Doyle F.J. Control-relevent modeling in drug delivery. Advanced Drug Delivery Reviews 2001, 48:211-228.
32. Piard C., Bressolle F., Fakhoury M., Zhang D., Yacouben K., Rieutord A., Jacqz-Aigrain E. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemotherapy Pharmacology 2007, 60:609-620.
33. Radivoyevitch T., Loparo K.A., Jackson R.C., Sedwick W.D. On systems and control approaches to therapeutic gain. BMC Cancer 2006, 6.
34. Relling M.V., Hancock M.L., Boyett J.M., Pui C.-H., Evans W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999, 93:2817-2823.
35. Richards S., Gray R., Peto R., Gaynon P., Masera G. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12000 randomised children. The Lancet 1996, 347:1783-1788.
36. Rivard G.E., Lin K.T., Leclerc J.M., David M. Milk could decrease the bioavailability of 6-mercaptopurine. American Journal of Pediatric Hematology/Oncology 1989, 11:402-406.
37. Saltelli A., Tarantola S., Chan K.P.-S. A quantitative model-independent method for global sensitivity analysis of model output. Technometrics 1999, 41:39-56.
38. Schmiegelow K., Bruunshuus I. 6-thioguanine nucleotide accumulation in red-blood-cells during maintenance chemotherapy for childhood acute lymphoblastic-leukemia, and its relation to leukopenia. Cancer Chemotherapy and Pharmacology 1990, 26:288-292.
39. Schmiegelow K., Schroder H., Schmiegelow M. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white blood cell counts or by pharmacokinetic parameters?. Cancer Chemotherapy Pharmacology 1994, 34:209-215.
40. Schmiegelow K., Glomstein A., Kristinsson J., Salmi T., Schroder H., Bjork O. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology 1997, 19:102-109.
41. Stanulla M., Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Seminars in Hematology 2009, 46:52-63.
42. Thomas C.W., Lowry P.W., Franklin C.L., Weaver A.L., Myhre G.M., Mays D.C., Tremaine W.J., Lipsky J.J., Sandborn W.J. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflammatory Bowel Diseases 2003, 9:237-245.
43. Thomsen J.B., Schroder H., Kristinsson J., Madsen B., Szumlanski C., Weinshilboum R., Andersen J.B., Schmiegelow K. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer 1999, 86:1080-1086.
44. van Eys J., Berry D., Crist W., Doering E., Fernbach D., Pullen J., Shuster J. Treatment intensity and outcome for children with acute lymphoblastic leukemia of standard risk: a pediatric oncology group study. Cancer 1989, 63:1466-1471.
45. Wang, Y., Dassau, E., Doyle III, F.J., 2009. Closed-loop control of artificial pancreatic Β-cell in type 1 diabetes mellitus using model predictive iterative learning control. IEEE Transactions on Biomedical Engineering, in press.
46. Waugh R.E., Narla M., Jackson C.W., Mueller T.J., Suzuki T., Dale G.L. Rheologic properties of senescent erythrocytes: loss of surface area and volume with red blood cell age. Blood 1992, 79:1351-1358.
47. Wheldon E.G., Lindsay K.A., Wheldon T.E., Mao J.-H. A two-stage model for childhood acute lymphoblastic leukemia: application to hereditary and nonhereditary leukemogenesis. Mathematical Biosciences 1997, 139:1-24.
48. Zurakowski R., Teel A.R. A model predictive control based scheduling method for HIV therapy. Journal of Theoretical Biology 2006, 238:368-382.